Cinoxacin: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
 
CSV import
Line 1: Line 1:
'''Cinoxacin''' is a synthetic [[antibacterial]] agent that belongs to the class of [[quinolone antibiotics]]. It is primarily used in the treatment of urinary tract infections (UTIs) caused by susceptible bacteria. Cinoxacin works by inhibiting the bacterial enzyme DNA gyrase, which is essential for DNA replication, transcription, repair, and recombination. This action leads to the death of the bacteria and the resolution of the infection.
{{Short description|An article about the antibiotic Cinoxacin}}
{{Drugbox
| verifiedrevid = 477241123
| image = Cinoxacin.svg
| image2 = <!-- Another image if available -->
}}
 
'''Cinoxacin''' is a [[synthetic antibiotic]] belonging to the [[quinolone]] class. It was primarily used to treat [[urinary tract infections]] (UTIs) caused by susceptible strains of bacteria. Although it was once a common treatment, it has largely been replaced by newer antibiotics with improved efficacy and safety profiles.


==Mechanism of Action==
==Mechanism of Action==
Cinoxacin exerts its antibacterial effect by targeting the DNA gyrase enzyme in bacteria. DNA gyrase is a type II topoisomerase that introduces negative supercoils into DNA, which is a critical step in DNA replication and transcription. By inhibiting this enzyme, cinoxacin prevents the replication of bacterial DNA, leading to the elimination of the bacteria causing the infection.
Cinoxacin works by inhibiting bacterial [[DNA gyrase]], an enzyme critical for [[DNA replication]] and [[transcription]]. By interfering with this enzyme, cinoxacin prevents bacteria from reproducing and repairing themselves, leading to bacterial cell death.
 
==Indications==
Cinoxacin is indicated for the treatment of acute, uncomplicated urinary tract infections caused by susceptible strains of the following microorganisms:
* [[Escherichia coli]]
* [[Proteus mirabilis]]
* [[Klebsiella pneumoniae]]
* [[Staphylococcus saprophyticus]]
 
It is important to note that cinoxacin is not recommended for the treatment of pyelonephritis or perinephric abscesses due to insufficient data supporting its efficacy in these conditions.


==Pharmacokinetics==
==Pharmacokinetics==
After oral administration, cinoxacin is absorbed from the gastrointestinal tract. Its bioavailability is approximately 90%, and peak plasma concentrations are reached within 1 to 2 hours. The presence of food can delay the absorption but does not significantly affect the overall bioavailability. Cinoxacin is minimally metabolized in the liver and is primarily excreted unchanged in the urine, where it achieves high concentrations that are effective against urinary pathogens.
Cinoxacin is administered orally and is well absorbed from the [[gastrointestinal tract]]. It is widely distributed throughout the body and is primarily excreted unchanged in the [[urine]]. This makes it particularly effective for treating infections of the urinary tract.


==Adverse Effects==
==Clinical Uses==
The most common adverse effects associated with cinoxacin include:
Cinoxacin was used to treat uncomplicated urinary tract infections caused by [[Escherichia coli]], [[Proteus mirabilis]], and other susceptible organisms. It was not effective against [[Pseudomonas aeruginosa]] or [[anaerobic bacteria]].
* Nausea
* Vomiting
* Diarrhea
* Rash
* Headache
* Dizziness


As with other quinolones, cinoxacin may cause tendinitis or tendon rupture, particularly in older adults, those on corticosteroid therapy, and in patients with kidney, heart, or lung transplants. Patients should be advised to stop taking cinoxacin at the first sign of tendon pain, swelling, or inflammation.
==Side Effects==
Common side effects of cinoxacin included [[nausea]], [[vomiting]], and [[diarrhea]]. Some patients experienced [[photosensitivity]], leading to increased risk of [[sunburn]]. Rarely, it could cause [[central nervous system]] effects such as [[dizziness]] and [[headache]].


==Contraindications==
==Resistance==
Cinoxacin is contraindicated in patients with a history of hypersensitivity to cinoxacin, other quinolones, or any component of the formulation. Caution is advised in patients with a history of seizure disorders, as quinolones may lower the seizure threshold.
Bacterial resistance to cinoxacin can develop through mutations in the genes encoding DNA gyrase or through efflux mechanisms that reduce drug accumulation in bacterial cells. The emergence of resistance has limited the use of cinoxacin in clinical practice.


==Drug Interactions==
==History==
Cinoxacin may interact with several other medications, including:
Cinoxacin was introduced in the 1970s as one of the first quinolone antibiotics. It was a precursor to the development of more advanced quinolones, such as [[ciprofloxacin]] and [[levofloxacin]], which have broader spectra of activity and improved pharmacokinetic properties.
* Antacids containing magnesium or aluminum, as well as sucralfate, can decrease the absorption of cinoxacin, leading to reduced efficacy.
* Caffeine: Cinoxacin may increase the half-life of caffeine, leading to increased effects or toxicity.
* Warfarin: Cinoxacin may enhance the effects of warfarin, increasing the risk of bleeding.


Patients should be advised to inform their healthcare provider of all medications they are taking, including over-the-counter drugs and dietary supplements.
==Discontinuation==
Due to the development of newer antibiotics with better safety and efficacy profiles, cinoxacin has been largely discontinued in many countries. It is no longer a first-line treatment for urinary tract infections.


==Conclusion==
==Related pages==
Cinoxacin is a quinolone antibiotic used in the treatment of uncomplicated urinary tract infections caused by susceptible bacteria. Its mechanism of action involves the inhibition of bacterial DNA gyrase, leading to bacterial cell death. While effective, it is associated with certain adverse effects and drug interactions that should be considered before use. As with all antibiotics, it is important to use cinoxacin as directed by a healthcare provider to ensure the best possible outcome and to help prevent the development of antibiotic resistance.
* [[Quinolone]]
* [[Urinary tract infection]]
* [[Antibiotic resistance]]


[[Category:Antibiotics]]
[[Category:Antibiotics]]
[[Category:Quinolone antibiotics]]
[[Category:Quinolones]]
 
{{medicine-stub}}

Revision as of 03:43, 13 February 2025

An article about the antibiotic Cinoxacin


Cinoxacin
File:Cinoxacin.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG


Cinoxacin is a synthetic antibiotic belonging to the quinolone class. It was primarily used to treat urinary tract infections (UTIs) caused by susceptible strains of bacteria. Although it was once a common treatment, it has largely been replaced by newer antibiotics with improved efficacy and safety profiles.

Mechanism of Action

Cinoxacin works by inhibiting bacterial DNA gyrase, an enzyme critical for DNA replication and transcription. By interfering with this enzyme, cinoxacin prevents bacteria from reproducing and repairing themselves, leading to bacterial cell death.

Pharmacokinetics

Cinoxacin is administered orally and is well absorbed from the gastrointestinal tract. It is widely distributed throughout the body and is primarily excreted unchanged in the urine. This makes it particularly effective for treating infections of the urinary tract.

Clinical Uses

Cinoxacin was used to treat uncomplicated urinary tract infections caused by Escherichia coli, Proteus mirabilis, and other susceptible organisms. It was not effective against Pseudomonas aeruginosa or anaerobic bacteria.

Side Effects

Common side effects of cinoxacin included nausea, vomiting, and diarrhea. Some patients experienced photosensitivity, leading to increased risk of sunburn. Rarely, it could cause central nervous system effects such as dizziness and headache.

Resistance

Bacterial resistance to cinoxacin can develop through mutations in the genes encoding DNA gyrase or through efflux mechanisms that reduce drug accumulation in bacterial cells. The emergence of resistance has limited the use of cinoxacin in clinical practice.

History

Cinoxacin was introduced in the 1970s as one of the first quinolone antibiotics. It was a precursor to the development of more advanced quinolones, such as ciprofloxacin and levofloxacin, which have broader spectra of activity and improved pharmacokinetic properties.

Discontinuation

Due to the development of newer antibiotics with better safety and efficacy profiles, cinoxacin has been largely discontinued in many countries. It is no longer a first-line treatment for urinary tract infections.

Related pages